All In Biotech

Drug Trial Radar · NCT06492291

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Aug 5, 2024

Primary completion

Oct 13, 2028

Study completion Oct 13, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).

Conditions

  • Hypercholesterolemia

Interventions

  • Enlicitide DecanoateDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with one or more adverse events (AEs)Time frame: Up to approximately 3 years
  2. Number of participants who discontinue study drug due to an AETime frame: Up to approximately 3 years

Locations

222 sites in 28 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC ( Site 0027)

    Daphne, Alabama

  • G&L Research ( Site 0035)

    Foley, Alabama

  • Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0048)

    Phoenix, Arizona

  • National Heart Institute-Research ( Site 0029)

    Beverly Hills, California

  • Clinical Trials Research ( Site 0054)

    Sacramento, California

  • Velocity Clinical Research, Banning ( Site 0023)

    San Bernardino, California

  • Emerson Clinical Research Institute ( Site 0017)

    Washington D.C., District of Columbia

  • Excel Medical Clinical Trials ( Site 0010)

    Boca Raton, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0037)

    Doral, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0056)

    Fort Myers, Florida

  • Velocity Clinical Research, Hallandale Beach ( Site 0053)

    Hallandale, Florida

  • Jacksonville Center for Clinical Research ( Site 0025)

    Jacksonville, Florida

  • South Broward Research ( Site 0012)

    Miramar, Florida

  • Progressive Medical Research ( Site 0033)

    Port Orange, Florida

  • Clinical Research Trials of Florida ( Site 0006)

    Tampa, Florida

  • Clinical Site Partners, LLC dba Flourish Research ( Site 0004)

    Winter Park, Florida

  • East Coast Institute for Research, LLC ( Site 0020)

    Macon, Georgia

  • Healthcare Research Network - Chicago ( Site 0051)

    Flossmoor, Illinois

  • Synexus Clinical Research US - Evansville ( Site 0005)

    Evansville, Indiana

  • Midwest Institute For Clinical Research ( Site 0052)

    Indianapolis, Indiana

  • Alliance for Multispecialty Research, LLC ( Site 0001)

    Lexington, Kentucky

  • L-MARC Research Center ( Site 0011)

    Louisville, Kentucky

  • Velocity Clinical Research, Covington ( Site 0026)

    Covington, Louisiana

  • Velocity Clinical Research Rockville ( Site 0022)

    Rockville, Maryland

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018)

    Troy, Michigan

  • Velocity Clinical Research, Gulfport ( Site 0032)

    Gulfport, Mississippi

  • Healthcare Research Network - St. Louis ( Site 0040)

    Hazelwood, Missouri

  • Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0031)

    Lincoln, Nebraska

  • Jubilee Clinical Research ( Site 0049)

    Las Vegas, Nevada

  • AB Clinical Trials ( Site 0002)

    Las Vegas, Nevada

  • New Mexico Clinical Research & Osteoporosis Center ( Site 0043)

    Albuquerque, New Mexico

  • Velocity Clinical Research, Syracuse ( Site 0014)

    East Syracuse, New York

  • Icahn School of Medicine at Mount Sinai-Cardiology ( Site 0042)

    New York, New York

  • Lillestol Research ( Site 0030)

    Fargo, North Dakota

  • altoona center for clinical research ( Site 0024)

    Duncansville, Pennsylvania

  • Cardiology Consultants of Philadelphia Yardley ( Site 0021)

    Yardley, Pennsylvania

  • Velocity Clinical Research, Anderson ( Site 0015)

    Anderson, South Carolina

  • Piedmont Research Partners ( Site 0045)

    Fort Mill, South Carolina

  • Coastal Carolina Research Center ( Site 0055)

    North Charleston, South Carolina

  • Monument Health Clinical Research, a department of Monument -Monument Health Clinical Research, a d ( Site 0038)

    Rapid City, South Dakota

Showing 40 of 222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.